4SA Stock Chart & Stats
€0.25
>-€0.01(-0.99%)
At close: 4:00 PM EDT
€0.25
>-€0.01(-0.99%)
Day’s Range― - ―
52-Week Range€0.12 - €0.41
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.14M
Enterprise Value€70.31M
Total Cash (Recent Filing)€9.48M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding21,163,902
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.27
Price to Sales (P/S)7.79
P/FCF Ratio-3.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€935.84K
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetNo reported debt materially lowers solvency and refinancing pressure, giving AcouSort greater flexibility while it develops and commercializes its acoustofluidic modules. This conservative financing profile can help preserve strategic options through the next several quarters despite current losses.
Revenue GrowthRevenue growth indicates that AcouSort is generating increasing demand for its technology, modules, or integration work. Continued expansion of the top line could improve operating leverage and support greater commercial scale, although profitability must still improve for this growth to create durable value.
Broad Technology ApplicationsAcouSort’s label-free acoustofluidic technology addresses several life-science applications rather than a single narrow use case. Exposure to cell therapy, diagnostics, and research broadens potential customer adoption and gives the company multiple avenues for longer-term commercialization.
Bears Say
Deeply Negative ProfitabilityNegative gross profit and substantial operating and net losses show that AcouSort has not yet established a stable, scalable profit model. Persistent losses can limit internal reinvestment capacity and make future performance highly dependent on achieving meaningful margin improvement.
Persistent Cash BurnOngoing negative operating and free cash flow means the business is consuming cash rather than funding its operations internally. The reversion from positive cash generation in 2022 to sizable recent burn indicates that funding needs may remain elevated until profitability improves.
Shrinking Equity BaseThe sharp decline in equity reflects the cumulative effect of ongoing losses and reduces the company’s financial buffer. If cash burn continues, AcouSort may need additional funding, creating potential dilution risk and limiting flexibility in allocating capital to growth initiatives.
4SA FAQ
What was AcouSort AB’s price range in the past 12 months?
AcouSort AB lowest stock price was €0.12 and its highest was €0.41 in the past 12 months.
What is AcouSort AB’s market cap?
AcouSort AB’s market cap is €6.14M.
When is AcouSort AB’s upcoming earnings report date?
AcouSort AB’s upcoming earnings report date is Nov 25, 2026 which is in 25 days.
How were AcouSort AB’s earnings last quarter?
AcouSort AB released its earnings results on Aug 26, 2026. The company reported -€0.015 earnings per share for the quarter.
Is AcouSort AB overvalued?
According to Wall Street analysts AcouSort AB’s price is currently Overvalued.
Does AcouSort AB pay dividends?
AcouSort AB does not currently pay dividends.
What is AcouSort AB’s EPS estimate?
AcouSort AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AcouSort AB have?
AcouSort AB has 21,163,902 shares outstanding.
What happened to AcouSort AB’s price movement after its last earnings report?
AcouSort AB reported an EPS of -€0.015 in its last earnings report. Following the earnings report the stock price went down -7.631%.
Which hedge fund is a major shareholder of AcouSort AB?
Currently, no hedge funds are holding shares in DE:4SA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AcouSort AB
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an module that enables in-line analysis of blood plasma from whole blood samples; AQC Module, an in-line optical analysis of particle suspensions for quality control or monitoring applications; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company has collaboration agreement with global life science company to develop cell therapy and other elements of the future automated systems. AcouSort AB (publ) was founded in 2010 and is based in Lund, Sweden.